What is Opus Genetics's enterprise value?

Opus Genetics (IRD) reported enterprise value of $264.97M in Q1 2026.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Opus Genetics IRD Enterprise value

Enterprise value at other companies

AbbVieABBV

$460.96B+24.7%

MeiraGTx Holdings plcMGTX

$696.49M+26.9%

4D Molecular TherapeuticsFDMT

$423.34M+961%

Opko HealthOPK

$918.12M-21.5%

Kodiak Sciences IncKOD

$2.21B+2,798%

Regeneron PharmaceuticalsREGN

$81.42B+18.1%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

$323.7Mmarket cap+$1.2Mtotal debt−$60.0Mcash and equivalents=$264.97M

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's enterprise value?: Opus Genetics (IRD) reported enterprise value of $264.97M in Q1 2026.
What does enterprise value mean?: Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.